European tick-borne encephalitis is caused by an RNA virus that is transmitted through infected ticks of subtype I. ricinus. Most cases of European tick-borne encephalitis are diagnosed in people over 50 years old because severity increases with age. Approximately one-third of individuals with the European tick-borne encephalitis infection show symptoms. These symptoms appear after 4-28 days and include headache, fatigue and myalgia. Some infected individuals are subject to the second phase of the disease, which causes symptoms such as meningitis, encephalitis, cognitive dysfuction, and ataxia. There is no cure or specific treatment for European tick-borne encephalitis other than supportive care. Two vaccines are available in Europe for adults and pediatric prevention of the European tick-borne encephalitis infection.
Tick-borne Encephalitides, European Bioinformatics Tool
Laverne is a handy bioinformatics tool to help facilitate scientific exploration of related genes, diseases and pathways based on co-citations. Explore more on Tick-borne Encephalitides, European below!
For more information on how to use Laverne, please read the How to Guide.
We have 554 products for the study of Tick-borne Encephalitides, European that can be applied to Western Blot, Flow Cytometry, Immunocytochemistry/Immunofluorescence, Immunohistochemistry from our catalog of antibodies and ELISA kits.